REGENXBIO Inc.
RGNX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 112.72M | 58.18M | -262.88M | -280.32M | -6.50 |
| 2023 FY | 90.24M | 53.03M | -268.13M | -263.49M | -6.02 |
| 2024 FY | 83.33M | 49.76M | -233.35M | -227.10M | -4.59 |
| 2025 FY | 170.44M | 150.14M | -161.20M | -193.88M | -3.76 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 833.27M | 317.07M | 96.95M | 94.80M | 516.20M |
| 2023 FY | 573.97M | 262.23M | 34.52M | 89.29M | 311.74M |
| 2024 FY | 465.99M | 206.34M | 57.53M | 82.03M | 259.65M |
| 2025 FY | 453.03M | 350.30M | 34.47M | 260.52M | 102.73M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -207.49M | -30.72M | -238.21M | — | -248.26M |
| 2023 FY | -218.41M | -9.96M | -228.37M | — | -62.43M |
| 2024 FY | -173.13M | -2.44M | -175.56M | — | 23.00M |
| 2025 FY | -123.96M | -2.41M | -126.38M | — | -23.06M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 978.69M | 976.53M | — | — | — |
| 2023 FY | 785.03M | 839.79M | — | — | — |
| 2024 FY | 382.70M | 407.21M | — | — | — |
| 2025 FY | 742.65M | 968.70M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 21.36M | 12.25M | -63.28M | -70.87M | -1.38 |
| 2025 Q3 | 29.73M | -32.09M | -52.41M | -61.94M | -1.20 |
| 2025 Q4 | 30.34M | 24.41M | -57.64M | -67.15M | -1.30 |
| 2026 Q1 | 6.39M | -4.68M | -83.36M | -90.05M | -1.72 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 581.03M | 367.35M | 79.56M | 77.70M | 213.68M |
| 2025 Q3 | 525.20M | 363.75M | 58.80M | 268.14M | 161.45M |
| 2025 Q4 | 453.03M | 350.30M | 34.47M | 260.52M | 102.73M |
| 2026 Q1 | 341.89M | 320.81M | 15.23M | 71.07M | 21.08M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -49.34M | -391.00K | -49.73M | — | -50.55M |
| 2025 Q3 | -55.96M | -491.00K | -56.45M | — | -20.76M |
| 2025 Q4 | -52.29M | -508.00K | -52.80M | — | -24.34M |
| 2026 Q1 | -76.19M | -1.24M | -77.42M | — | -19.24M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 422.68M | 420.81M | — | — | — |
| 2025 Q3 | 498.80M | 708.14M | — | — | — |
| 2025 Q4 | 745.23M | 971.28M | — | — | — |
| 2026 Q1 | 439.35M | 495.18M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |